Category: Artificial Tissue

Artificial Tissue

Organogenesis, Advanced Biohealing stand to benefit from CMS proposal

July 6, 2010 by MassDevice staff

A temporary proposal from the Centers for Medicare and Medicaid Services could be a boon for Organogenesis Inc. and Advanced BioHealing Inc. and their artificial skin treatments for diabetic foot ulcers.

Organogenesis Inc. and Advanced BioHealing Inc. may win a new reimbursement code for their skin regenerating systems.

The Centers for Medicare and Medicaid Services proposed temporary, updated coding for artificial skin products in treating diabetic foot ulcers, slated to take effect in 2011.

The proposal would standardize the reimbursement codes for the Apligraf product made by Canton, Mass.-based Organogenesis and Advanced BioHealing's Dermagraft, which now are reimbursed according to different schemes.

Stratatech plans clinical trial for skin substitute

May 5, 2010 by MedCity News

Stratatech Corp. wastes no time after a $3 million funding round in announcing plans for a Phase IIb clinical trial of its StrataGraft skin substitute.

By Brandon Glenn

Fresh off a $3 million funding round, Stratatech Corp. plans to begin Phase IIb clinical trials of its genetically engineered human skin substitute.

Stratatech raises $3 million

April 8, 2010 by MedCity News

Skin substitute developer Stratatech Corp. raises $3 million in an offering of debt, options, warrants and other securities.

By Brandon Glenn

Stratatech Corp. raised $3 million to continue developing a genetically engineered human skin substitute, according to a regulatory filing.

The investment comes in the form of debt, options, warrants or other securities, according to the Securities & Exchange Commission filing. Vice president and treasurer Robert Barnard declined to comment on the round.

UPDATE: Advanced BioHealing launches Dermagraft trial

November 18, 2009 by MassDevice staff

The Westport, Conn.-based tissue regeneration company will study the effectiveness of its bio-engineering skin substitute in helping venous leg ulcers to heal, in the largest-ever randomized, controlled clinical study of bioengineered skin replacement

From snip, snip to step, step in only a few months.

Advanced BioHealing Inc. launched a Phase III clinical trial of its Dermagraft bio-engineered skin substitute in patients with venous leg ulcers.

The Westport, Conn.-based tissue regeneration company said the Dermagraft is designed to help restore damaged tissue and support the body's natural healing process. The Food & Drug Administration already cleared the product to treat diabetic foot ulcers; ABH said more than 1,000 wound care and outpatient clinics in the U.S. use it.

ACell Inc.

6 Old Dee Rd

Cambridge

02142

United States

(800) 826-2926

www.acell.com

Product(s):

Develops wound care products using biologic scaffolding

CEO:

James DeFrancesco

Management:

Miles Grody, CFO

Ralph Leasure, Executive Vice President, Sales & Marketing

Report: Tissue regeneration market to grow to 16 percent a year to $118 billion by 2013

March 4, 2009 by MassDevice staff

Companies making tissue-regenerative products can expect a boom market over the next five years, according to Life Science Intelligence.

The global market for tissue-regenerative products could enjoy a growth rate of 16 percent a year through 2013, when it might be worth more than $118 billion, according to market research firm Life Science Intelligence.

According to the group’s Worldwide Markets and Emerging Technologies for Tissue Engineering and Regenerative Medicine, the global tissue engineering and regenerative medicine market was worth about $1.5 billion last year. If it grows at a 16 percent clip, the market should reach $1.7 billion this year and top $2 billion in 2010.